1-[(2R,3R,4R,5S)-5-[({[({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium-3-carboxylate

• ChemBase编号: 3721
• 分子式: C21H26N6O15P2
• 平均质量: 664.409862
• 单一同位素质量: 664.09313742
• SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@@H](CO[P@@](=O)(O)O[P@](=O)(O)OC[C@@H]2O[C@H]([C@H](O)[C@H]2O)[n+]2cccc(c2)C(=O)[O-])[C@H](O)[C@H]1O
• Canonical SMILES: O[C@@H]1[C@@H](O)[C@@H](O[C@H]1[n+]1cccc(c1)C(=O)[O-])CO[P@](=O)(O[P@@](=O)(OC[C@@H]1O[C@H]([C@@H]([C@H]1O)O)n1cnc2c1ncnc2N)O)O
• InChI: InChI=1S/C21H26N6O15P2/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(31)14(29)11(41-20)6-39-44(36,37)42-43(34,35)38-5-10-13(28)15(30)19(40-10)26-3-1-2-9(4-26)21(32)33/h1-4,7-8,10-11,13-16,19-20,28-31H,5-6H2,(H4-,22,23,24,32,33,34,35,36,37)/t10-,11-,13-,14-,15+,16+,19+,20+/m0/s1
• InChIKey: SENPVEZBRZQVST-AAIUHBJKSA-N

名称和登记号

名称

• IUPAC标准名: 1-[(2R,3R,4R,5S)-5-[({[({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium-3-carboxylate
• IUPAC传统名: 1-[(2R,3R,4R,5S)-5-{[({[(2S,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy(hydroxy)phosphoryl)oxy]methyl}-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium-3-carboxylate
• 别名: Deamido-Nad+

登记号

• PubChem SID: 46507165; 160967159
• PubChem CID: 6336819; 70789236

理论计算性质

JChem

• Acid pKa: -7.028098
• 质子受体: 16
• 质子供体: 7
• LogD (pH = 5.5): -11.780618
• LogD (pH = 7.4): -12.030616
• Log P: -9.903883
• 摩尔折射率: 151.0118 cm^3
• 极化性: 55.764812 Å^3
• 极化表面积: 315.3 Å^2
• 可自由旋转的化学键: 11
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -0.89
• LOG S: -2.57
• 溶解度: 1.88e+00 g/l

详细说明

DrugBank - DB04099

Drug information: experimental